Blue Trust Inc. Has $57,000 Position in Icon Plc $ICLR

Blue Trust Inc. raised its stake in Icon Plc (NASDAQ:ICLR) by 44.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 393 shares of the medical research company’s stock after purchasing an additional 120 shares during the period. Blue Trust Inc.’s holdings in Icon were worth $57,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC boosted its position in shares of Icon by 22.8% in the first quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company’s stock valued at $99,000 after acquiring an additional 110 shares during the period. Financiere des Professionnels Fonds d investissement inc. boosted its position in shares of Icon by 31.0% in the second quarter. Financiere des Professionnels Fonds d investissement inc. now owns 50,212 shares of the medical research company’s stock valued at $7,303,000 after acquiring an additional 11,894 shares during the period. Greenhaven Associates Inc. bought a new stake in shares of Icon in the second quarter valued at about $2,565,000. DAVENPORT & Co LLC bought a new stake in shares of Icon in the second quarter valued at about $403,000. Finally, Canoe Financial LP boosted its position in shares of Icon by 10.3% in the second quarter. Canoe Financial LP now owns 193,851 shares of the medical research company’s stock valued at $28,196,000 after acquiring an additional 18,174 shares during the period. Institutional investors own 95.61% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ICLR. Citigroup reissued a “neutral” rating and issued a $200.00 target price (down previously from $225.00) on shares of Icon in a research report on Thursday, August 21st. Baird R W raised shares of Icon from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 24th. Robert W. Baird upped their price objective on shares of Icon from $222.00 to $224.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Cowen reaffirmed a “hold” rating on shares of Icon in a research report on Friday, September 12th. Finally, Evercore ISI upped their price objective on shares of Icon from $170.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, July 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $210.64.

Icon Stock Down 1.8%

ICLR stock opened at $185.06 on Friday. The stock has a market capitalization of $14.95 billion, a P/E ratio of 19.04, a price-to-earnings-growth ratio of 2.75 and a beta of 1.23. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35. Icon Plc has a 12 month low of $125.10 and a 12 month high of $301.45. The firm has a 50-day moving average price of $177.18 and a 200-day moving average price of $157.31.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.08. The firm had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Icon had a net margin of 9.82% and a return on equity of 10.95%. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.75 earnings per share. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. As a group, equities research analysts anticipate that Icon Plc will post 13.38 EPS for the current fiscal year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.